Inventor
MAUS MARCELA
US15 patents
⚠️ This page may combine multiple inventors who share the name “MAUS MARCELA”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
UNIV PENNSYLVANIA
6 patentsUS7745140B2Jun 29, 2010
Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
UNIV PENNSYLVANIA85 citations96
US7638326B2Dec 29, 2009
Activation and expansion of T-cells using an engineered multivalent signaling platform
UNIV PENNSYLVANIA68 citations96
US7638325B2Dec 29, 2009
Activation and expansion of T-cells using an engineered multivalent signaling platform
UNIV PENNSYLVANIA35 citations91
US7670781B2Mar 2, 2010
Activation and expansion of T-cells using an agent that provides a primary activation signal and another agent that provides a co-stimulatory signal
UNIV PENNSYLVANIA11 citations83
US10357514B2Jul 23, 2019
Treatment of cancer using anti-CD19 Chimeric Antigen Receptor
UNIV PENNSYLVANIA18 citations82
US9453199B2Sep 27, 2016
Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
UNIV PENNSYLVANIA1 citations58
NOVARTIS AG
5 patentsUS10221245B2Mar 5, 2019
Treatment of cancer using humanized anti-CD19 chimeric antigen receptor
NOVARTIS AG36 citations94
US10927184B2Feb 23, 2021
Treatment of cancer using humanized anti-CD19 chimeric antigen receptor
NOVARTIS AG10 citations86
US10308717B2Jun 4, 2019
Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor
NOVARTIS AG4 citations83
US11865167B2Jan 9, 2024
Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor
NOVARTIS AG2 citations72
US12559562B2Feb 24, 2026
Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor
NOVARTIS AG0 citations62